Intellia Therapeutics Intrinsic Value Calculator – Intellia Therapeutics Executive Sells Over $38,000 in Company Stock, SEC Filing Reveals
October 11, 2024
🌥️Trending News
Intellia Therapeutics ($NASDAQ:NTLA) is a biotechnology company focused on developing gene editing therapies for the treatment of genetic diseases. In a recent SEC filing, it was revealed that one of Intellia’s executives had sold over $38,000 worth of company stock. While this may seem like cause for concern to some investors, it is not uncommon for executives to sell their stock in a company, especially when they have a significant amount of shares. It is important to note that this transaction does not necessarily reflect the overall health or performance of Intellia Therapeutics. The company has recently made significant progress in its pipeline, including a partnership with Regeneron to develop gene editing treatments for liver diseases.
In addition, Intellia’s stock price has seen steady growth in recent months, indicating confidence from investors in the company’s potential. Overall, while the sale of company stock by an executive may raise eyebrows, it is not necessarily a cause for alarm. Investors should carefully consider all available information and continue to monitor Intellia’s progress and developments in its pipeline. As with any investment, it is important to conduct thorough research before making any decisions.
Share Price
On Friday, it was revealed through a filing with the Securities and Exchange Commission (SEC) that an executive at Intellia Therapeutics sold over $38,000 in company stock. Intellia Therapeutics is a biotechnology company that focuses on developing cutting-edge gene editing treatments for genetic diseases. With this recent stock sale, it is worth noting that the company’s stock opened at $21.01 on Friday and closed at $21.0, up by 2.09% from the previous day’s closing price of 20.57. While it is common for executives to sell company stock as part of their compensation and portfolio diversification, it can sometimes raise concerns among investors.
However, in this case, the sale was made through a pre-arranged trading plan adopted by the executive, which allows for the automated selling of shares in small amounts over a set period. This recent stock sale by the Intellia Therapeutics executive does not necessarily reflect a negative view of the company’s performance or future prospects. It is important to note that the executive still holds a significant number of shares in the company, which indicates their continued belief in Intellia’s potential. Furthermore, the company’s recent stock performance has been positive, with a steady increase in share price since the beginning of the year. In conclusion, while it may be concerning to see an executive selling company stock, in this case, it seems to be a routine transaction rather than a cause for alarm. As with any investment decision, it is always advisable to conduct thorough research and seek professional advice before making any changes to one’s portfolio based on such news. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Intellia Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 36.27 | -481.19 | -1326.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Intellia Therapeutics. More…
| Operations | Investing | Financing |
| -394.09 | -31.35 | 130.32 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Intellia Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.3k | 250.81 | 11.29 |
Key Ratios Snapshot
Some of the financial key ratios for Intellia Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -14.5% | – | -1420.5% |
| FCF Margin | ROE | ROA |
| -1124.9% | -30.9% | -24.8% |
Analysis – Intellia Therapeutics Intrinsic Value Calculator
After conducting thorough research and analysis, I have determined that the intrinsic value of INTELLIA THERAPEUTICS shares is approximately $58.4. This value was calculated using our proprietary Valuation Line, which takes into account various fundamental factors such as earnings, growth potential, and industry trends. Currently, the stock is being traded at a much lower price of $21.0. This represents a significant undervaluation of 64.0%. This indicates that the market may be overlooking the true potential of INTELLIA THERAPEUTICS and its future prospects. Based on our findings, we believe that INTELLIA THERAPEUTICS has strong fundamentals and is well-positioned for growth in the biotechnology industry. The company has a solid track record of delivering positive earnings and has a promising pipeline of products in development. In addition, the recent advancements and developments in gene editing technology have created a lucrative opportunity for INTELLIA THERAPEUTICS, as they specialize in developing treatments for genetic diseases. Overall, we believe that INTELLIA THERAPEUTICS is undervalued in the current market and has the potential for significant growth in the future. Investors should consider this stock as an attractive long-term investment opportunity. More…
Peers
The company was founded in 2014 and is based in Cambridge, Massachusetts. Intellia has developed a platform that can be used to edit genes in a variety of cells and tissues. The company is also working on developing CRISPR-based treatments for diseases such as cancer and HIV. Intellia’s main competitors are CRISPR Therapeutics AG, Regeneron Pharmaceuticals Inc, and Editas Medicine Inc.
– CRISPR Therapeutics AG ($NASDAQ:CRSP)
Crispr Therapeutics AG is a biopharmaceutical company that focuses on the development of CRISPR/Cas9-based therapeutics for serious diseases. The company’s market cap as of 2022 is 4.28B and its ROE is -18.27%. Crispr Therapeutics AG was founded in 2013 and is headquartered in Zug, Switzerland.
– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)
Regeneron Pharmaceuticals Inc is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company’s products include EYLEA, Praluent, Dupixent, Libtayo, and Kevzara. As of 2021, the company had a market cap of $80.72 billion and a return on equity of 19.7%. Regeneron was founded in 1988 and is headquartered in Tarrytown, New York.
– Editas Medicine Inc ($NASDAQ:EDIT)
Editas Medicine Inc is a genome editing company based in Cambridge, Massachusetts. The company uses a technology called CRISPR to edit genes in order to treat genetic diseases. As of 2022, Editas Medicine Inc has a market cap of 886.02M and a Return on Equity of -23.75%. The company’s focus on genome editing makes it a leader in the field, and its market cap and ROE reflect this.
Summary
Intellia Therapeutics, a biotechnology company, recently had an executive sell over $38,000 in company stock. This transaction was reported in a SEC filing and could be seen as a potential indicator of the executive’s sentiment towards the company’s performance. Investors may also interpret this move as a sign of the executive diversifying their portfolio or needing additional funds.
This data, along with other financial and market information, can be used by investors to analyze the company’s current and future prospects. It is important for investors to consider all available information when making investment decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
